Evidence map›Paper›PMID 19070984›Full record

ArticleJournal of pharmaceutical and biomedical analysis2009

Development of a gel permeation chromatographic assay to achieve mass balance in cellulose acetate phthalate stability studies.

James W Mayhew, Lulu T Gideon, Bryan Ericksen, John J Hlavaty, Simon M Yeh, Charles G Chavdarian, Nathan Strick, A Robert Neurath

Abstract read
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James W MayhewDow Pharmaceutical Sciences, Inc., 1330 Redwood Way, Petaluma, CA 94954, USA.
Lulu T Gideon
Bryan Ericksen
John J Hlavaty
Simon M Yeh
Charles G Chavdarian
Nathan Strick
A Robert Neurath

Funding

SAFETY AND EFFICACY OF CAP IN VIVOP01HD041761 · NICHD · NEW YORK BLOOD CENTER · PI NEURATH, A ROBERT ROBERT · 2001 to 2004
$4.2M
In vivo Safety and Efficacy of CAP and Combination FilmsU19HD048957 · NICHD · NEW YORK BLOOD CENTER · PI JIANG, SHIBO · 2004 to 2006
$3.9M
In vivo Safety and Efficacy of CAP and Combination FilmsU19AI076964 · NIAID · NEW YORK BLOOD CENTER · PI NEURATH, A ROBERT ROBERT · 2007 to 2008
$2.3M
NIAID NIH HHS U19 AI076964NICHD NIH HHS P01 HD041761NICHD NIH HHS P01 HD41761NICHD NIH HHS U19 HD048957
6 · The paper itself

Abstract

Cellulose acetate phthalate (CAP, cellulose acetate 1,2-benzenedicarboxylate) is a common polymeric oral tablet coating. CAP is also a vaginal microbicide candidate that potently inhibits HIV-1 proliferation. This paper describes the development of a precise, stability-indicating gel permeation chromatography (GPC) assay for CAP. During accelerated stability studies monitored by separate reversed-phase high performance liquid chromatography (RP-HPLC) and GPC analyses, an apparent loss of mass balance was observed. This deficit was corrected by recalculating the response factor (RF) for each degraded sample, proportional to the fraction of phthalate remaining bound to the polymeric CAP. The correction factor enabled CAP and the degradation product phthalic acid (PA) to be quantitated by a single GPC analysis. The chromatographic approach taken here could potentially apply to any polymer containing degradable chromophores.

Indexed as

Anti-HIV AgentsCelluloseChromatography, GelChromatography, High Pressure LiquidDrug StabilityFemaleHIV-1HumansHydrolysisMolecular StructureReproducibility of ResultsSolutionsSolventsAnti-HIV AgentsCellulosecellulose acetate phthalateSolutionsSolvents

Identifiers

PMID19070984
PMCPMC2859192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.